R+DA-EPOCH方案治疗弥漫大B细胞淋巴瘤的疗效  

Therapeutic effect of Rituximab combined with DA-EPOCH on DLBCL

作　　者：胡茂贵 丁凯阳 宋浩 吴国林 王馨辰 HU Maogui;DING Kaiyang;SONG Hao(Department of Hematology,the First Affiliated Hospital of USTC West District(Anhui Provincial Cancer Hospital),Hefei 230031,China)

机构地区：[1]中国科学技术大学附属第一医院西区(安徽省肿瘤医院)血液科,合肥230031

出　　处：《安徽医学》2020年第7期748-751,共4页Anhui Medical Journal

基　　金：安徽省2018年度重点研究与开发计划项目(项目编号:1804h08020249)。

摘　　要：目的探讨R+DA-EPOCH方案治疗弥漫大B细胞淋巴瘤(DLBCL)的临床疗效和安全性。方法选择2015年5月至2018年1月中国科学技术大学附属第一医院西区(安徽省肿瘤医院)收治的30例初治DLBCL患者,采用R+DA-EPOCH方案治疗,评价临床疗效与安全性。结果30例患者中,完全缓解(CR)14例(46.67%),部分缓解(PR)7例(23.33%)。双重表达淋巴瘤患者治疗有效率为92.31%,非双重表达淋巴瘤患者治疗有效率为52.94%,差异具有统计学意义(P<0.05)。24个月的无进展生存期(PFS)率为86.54%,至随访终点的PFS率为78.67%。结论R+DA-EPOCH方案对于DLBCL的有效率较高,尤其可克服双重表达对疾病预后的影响,不良反应可耐受,安全性高,值得临床推广应用。Objective To observe the clinical efficacy and safety of R+DA-EPOCH regimen in the treatment of diffuse large B-cell lymphoma(DLBCL).Methods Thirty patients with DLBCL admitted from May 2015 to January 2018 were treated with R+DA-EPOCH.The clinical efficacy and safety were evaluated.Results Among all patients,14 patients(46.67%)had complete response(CR)and 7 patients(23.33%)had partial response(PR).The response rate was 92.31%in DPL patients and 52.94%in non DPL patients,and the difference was statistically significant(P<0.05).The 24 months’PFS rate was 86.54%,and the PFS rate was 78.67%at the endpoint.Conclusions It is worth while to popularize the R+DA-EPOCH regimen for its high overall response rate in DLBCL,especially its capacity overcome the double expression on prognosis,as well as its high tolerance and safety.

关 键 词：利妥昔单抗 弥漫大B细胞淋巴瘤 DA-EPOCH方案 疗效 

分 类 号：R733.1[医药卫生—肿瘤]